Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine plus HD-tIPNS for tinnitus
ACTRN12621000119897Phase 2Recruiting
- Sponsor
- Dirk De Ridder
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ketamine in tinnitus, sponsored by Dirk De Ridder. Primary endpoints: Tinnitus Functional Index, Feasibility outcomes and 1 more. Started May 2021; status: recruiting.
02
Drugs
ketamine
03
Conditions
tinnitus
Beyond the preview
Go deeper on ACTRN12621000119897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000119897.